YKP 1447

Drug Profile

YKP 1447

Alternative Names: YKP-1358; YKP-1447

Latest Information Update: 11 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SK biopharmaceuticals
  • Class Alkaloids; Antipsychotics; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists; Dopamine D3 receptor antagonists; Serotonin 2A receptor antagonists; Serotonin 2C receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Schizophrenia

Most Recent Events

  • 10 Apr 2008 Preclinical pharmacodynamics and adverse events data presented at the 235th National Meeting of the American Chemical Society (ACS-2008)
  • 06 Jul 2004 Phase-I clinical trials of YKP 1358 in Schizophrenia in USA (PO)
  • 24 Mar 2004 Preclinical trials of YKP 1358 in Schizophrenia in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top